Page 49 - 《中国药房》2023年15期
P. 49

新型肺靶向多西他赛脂质体在原位肺癌模型兔中的药动学研究
                                                                                                           Δ


                                  3
                 1*
                                          4
          王丽娟 ,李 睿 ,车坷科 ,余 瑜(1.重庆医药高等专科学校药学院/重庆药物制剂工程中心,重庆 401331;
                          2
          2.重庆药友制药有限责任公司,重庆 401121;3.重庆市人民医院药学部,重庆 400014;4.重庆医科大学药学院,
          重庆 400016)

          中图分类号  R969.1;R944      文献标志码  A      文章编号  1001-0408(2023)15-1835-05
          DOI  10.6039/j.issn.1001-0408.2023.15.09

          摘  要  目的  研究新型肺靶向多西他赛脂质体(DTX-LP)在原位肺癌模型兔中的药动学行为。方法  采用超高效液相色谱-二级
          串联质谱(UPLC-MS/MS)法测定DTX在兔血浆中的含量,并进行方法学考察。采用胸腔微创穿刺术制备原位肺癌模型兔,然后
          随机分为多西他赛注射液(DTX-IN)组和DTX-LP组,耳缘静脉注射给予相应药物,给药剂量均为1.0 mg/kg(以DTX计),然后于
          5、15、30、60、90、120、240、480 min时取血,测定血浆中DTX浓度。采用DAS 3.3软件进行拟合与分析,并计算药动学参数。结果
          本研究所用UPLC-MS/MS法的准确度、精密度良好,符合生物样品分析要求。与DTX-IN组比较,DTX-LP组的药-时曲线趋势较
          平缓,各时间点的血药浓度更低,cmax、t1/2、AUC0→480 min、AUC0→∞均显著降低(P<0.05)。结论  DTX-LP 在血浆中的暴露量较 DTX-IN
          降低,提示其能快速地从体循环中分布到肺靶器官。
          关键词  多西他赛;脂质体;原位肺癌模型;药动学


          Study on pharmacokinetics of novel lung-targeted Docetaxel liposome in in-situ lung cancer model rabbit
          WANG Lijuan ,LI Rui ,CHE Keke ,YU Yu(1.  School  of  Pharmacy,  Chongqing  Medical  and  Pharmaceutical
                                         3
                                                  4
                              2
                      1
          College/Chongqing  Engineering  Research  Center  of  Pharmaceutical  Sciences,  Chongqing  401331,  China;
          2.  Yaopharma  Co.,  Ltd.,  Chongqing  401121,  China;3.  Dept.  of  Pharmacy,  Chongqing  General  Hospital,
          Chongqing 400014, China;4. College of Pharmacy, Chongqing Medical University, Chongqing 400016, China)
          ABSTRACT   OBJECTIVE  To  study  the  pharmacokinetic  behavior  of  novel  lung-targeted  Docetaxel  liposome (DTX-LP)  in  in-
          situ  lung  cancer  model  rabbit.  METHODS  The  content  of  DTX  in  rabbit  plasma  was  determined  by  UPLC-MS/MS,  and
          methodology  investigation  was  conducted.  in-situ  lung  cancer  model  rabbit  was  made  by  the  ultra-minimal  invasive  percutaneous
          puncture  inoculation  method.  Model  rabbits  were  randomly  divided  into  Docetaxel  injection (DTX-IN)  group  and  DTX-LP  group.
          The rabbits were given relevant medicine via ear vein at a dose of 1.0 mg/kg (calculated by DTX); blood was taken at 5, 15, 30,
          60, 90, 120, 240 and 480 minutes to measure the concentration of DTX in plasma. DAS 3.3 software was adopted for fitting and
          analysis,  and  to  calculate  pharmacokinetic  parameters.  RESULTS  UPLC-MS/MS  method  used  in  this  study  was  accurate  and
          precise, which met the requirements of biological sample analysis. Compared with DTX-IN group, drug concentration-time curve of
          DTX-LP  was  smoother,  the  blood  concentration  at  each  time  point  was  lower,  and  cmax,  t1/2,  AUC0→480 min  and  AUC0→∞ were
          significantly  decreased (P<0.05).  CONCLUSIONS  The  drug  exposure  of  DTX-LP  in  plasma  is  significantly  reduced  than  DTX-
          IN, indicating it can be rapidly distributed from systemic circulation to liver target organs.
          KEYWORDS    docetaxel; liposome; in-situ lung cancer model; pharmacokinetics



              多西他赛(docetaxel,DTX)是紫杉烷类化疗药物,                  即选择性地分布于肺部肿瘤,从而有利于发挥DTX的疗
          也是肺癌常用的化疗药物之一,但其临床治疗效果常受                           效并降低其非靶组织的毒副作用。目前上市的DTX只
          制于体内非选择性分布所带来的副作用                    [1―2] 。因此,    有静脉注射用溶液剂一个剂型。近年来文献报道了一
          DTX治疗肺癌的关键是提高其在肺部肿瘤组织的浓度,                          些 DTX 新制剂,如纳米粒        [3―5] 、纳米脂质体 、pH 敏感脂
                                                                                                  [6]
                                                                 [7]
                                                             质体 、胶束    [8―9] 、微球 [10―11] 等,旨在改善溶液剂存在的肿
             Δ  基金项目 重 庆 市 教 育 委 员 会 科 学 技 术 研 究 项 目(No.
                                                             瘤部位靶向性不强、增溶剂用量或药物剂量过高等问
          KJQN202102805)
                                                             题。但这些制剂在提高DTX疗效、稳定性,降低毒副作
             *第一作者 副教授,博士。研究方向:药物新剂型与新技术。
          E-mail:aywlj@126.com                               用,促进工业化生产方面均存在明显的不足,如DTX在

          中国药房  2023年第34卷第15期                                              China Pharmacy  2023 Vol. 34  No. 15    · 1835 ·
   44   45   46   47   48   49   50   51   52   53   54